Sender CO & Partners, Inc. Celldex Therapeutics, Inc. Transaction History
Sender CO & Partners, Inc.
- $182 Million
- Q2 2025
A detailed history of Sender CO & Partners, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Sender CO & Partners, Inc. holds 15,593 shares of CLDX stock, worth $411,811. This represents 0.17% of its overall portfolio holdings.
Number of Shares
15,593Holding current value
$411,811% of portfolio
0.17%Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
198Shares Held
68.2MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$161 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$138 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$124 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$105 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$101 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.24B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...